0
0
Read Time:6 Minute, 11 Second
NEW DELHI — In a major push toward making early cancer detection accessible to millions of women, the Indian government’s Department of Science & Technology has pledged financial and institutional backing to commercialize an indigenous, artificial intelligence (AI)-enabled cervical cancer screening device.
The agreement, finalized between the Technology Development Board (TDB) and Vishakhapatnam-based M/s Griva Healthcare Pvt. Ltd., will scale up the manufacturing of “GrivaVision”—a portable digital colposcope designed to identify pre-cancerous cervical lesions in primary healthcare settings. The initiative aims to dramatically lower screening costs, reduce reliance on imported diagnostic machinery, and bridge the massive urban-rural gap in women’s preventive healthcare.
A Preventable Crisis: The Cervical Cancer Burden
Cervical cancer remains one of the most pressing public health challenges for women across low- and middle-income countries. According to the World Health Organization (WHO), cervical cancer is the fourth most common cancer in women globally, with an estimated 660,000 new cases and 350,000 deaths reported in 2022 alone. India accounts for a significant portion of this global burden, representing nearly one-fifth of all global deaths linked to the disease.
Despite being largely preventable through human papillomavirus (HPV) vaccination and regular routine screening, cervical cancer continues to claim lives primarily due to late-stage diagnosis.
┌── Primary Screening: HPV DNA / Pap Smear
│
┌── Early Detection & Prevention ───┼── Secondary Visual Triage: Colposcopy (e.g., GrivaVision)
│ │
│ └── Immediate Pre-Cancer Treatment (Ablation/LEEP)
Cervical ─┤
Control │ ┌── Advanced Stage Surgery
│ │
└── Late-Stage Intervention ────────┼── Chemotherapy
│
└── Radiation Therapy
“The tragedy of cervical cancer is that it develops slowly over many years,” explains Dr. Sunita Rao, a senior gynecological oncologist at the All India Institute of Medical Sciences (AIIMS), Delhi, who was not involved in the project’s development. “If pre-cancerous changes in the cervix are identified early, they can be treated simply and completely in an outpatient setting. The challenge in developing nations has never been a lack of treatment methods; it has been the inability to perform high-quality screening outside major tertiary hospitals.”
Traditional screening methods—such as the Papanicolaou (Pap) smear—require cytopathology laboratories and trained personnel, resources that are often sparse in rural and community clinics. While standard colposcopy allows doctors to visually inspect the cervix under magnification, traditional equipment is bulky, expensive, and requires extensive clinical expertise to interpret accurately.
How “GrivaVision” Works: Merging AI with Portability
GrivaVision addresses these infrastructure bottlenecks by consolidating multi-component laboratory equipment into a handheld, point-of-care platform.
The device combines high-definition optical cameras, integrated lighting, an in-built display screen, and proprietary AI-driven software. When a healthcare worker examines the vaginal canal, the device captures high-resolution digital images of the cervix. The internal AI software then analyzes the visual patterns in real time, assisting clinicians in distinguishing healthy tissue from pre-cancerous lesions.
+-----------------------------------------------------------------------------------+
| GrivaVision Architecture |
+-----------------------------------------------------------------------------------+
| [ HD Optics & Lighting ] ---> [ Real-Time Display ] |
| | |
| v |
| [ ABDM Digital Records ] <--- [ Indigenous AI Engine (WHO-AVE Aligned) ] |
+-----------------------------------------------------------------------------------+
Key features of the technology include:
-
WHO Compliance: Developed in alignment with the World Health Organization’s Automated Visual Evaluation (AVE) standards for visual inspection.
-
Regulatory & Quality Assurance: Classified as a Class B non-invasive medical device under the Central Drugs Standard Control Organisation (CDSCO) guidelines and manufactured in compliance with ISO 13485 quality standards.
-
Digital Integration: The software is compliant with the Ayushman Bharat Digital Mission (ABDM), allowing seamless transmission of patient records and diagnostic data to centralized health stacks.
-
High Localization: Over 50% of the device components are sourced within India, featuring proprietary hardware architecture patented locally.
Currently conducting research and development at the AIC-AMTZ Medivalley medical technology cluster in Visakhapatnam, Griva Healthcare will utilize TDB’s funding to set up a commercial manufacturing facility in Kollam, Kerala.
Strengthening Domestic Health Systems
The alliance between government funding and private biotech innovation reflects a growing effort toward self-reliance in advanced medical manufacturing. By transitioning the device from prototype status to commercial-scale output, public health experts anticipate a notable reduction in unit costs compared to imported colposcopes from Western manufacturers.
“Early detection can make a decisive difference in addressing cervical cancer,” said Shri Rajesh Kumar Pathak, Secretary of the Technology Development Board, during the announcement. “Indigenous technologies such as GrivaVision demonstrate how medical devices, digital health, and artificial intelligence can come together to address a critical healthcare need at scale. TDB’s support is aimed at taking such home-grown innovations from technology development to commercial manufacturing, making advanced screening solutions more accessible while strengthening India’s self-reliance in medical technologies.”
Leadership from Griva Healthcare echoed this objective, noting that expanding manufacturing to Kerala will bring reliable diagnostic tools closer to women residing in underserved, resource-constrained regions where specialized gynecological care remains out of reach.
Considerations and Counterarguments
While AI-assisted point-of-care diagnostics present a promising frontier for public health, medical experts advocate for cautious optimism and rigorous field deployment protocols.
| Consideration Area | Opportunities & Benefits | Potential Challenges & Limitations |
| Accessibility | Decentralizes screening to primary health centers and rural clinics. | Requires stable electricity and routine calibration in remote areas. |
| Diagnostic Accuracy | AI reduces subjective human error in visual inspections. | Algorithms require continuous training across diverse patient demographics to prevent false positives/negatives. |
| Healthcare Workflow | Enables immediate triage and quicker referral pathways. | Requires structured training for non-specialist healthcare workers operating the device. |
| Data Infrastructure | Integrates with national digital health stacks (ABDM). | Demands robust patient privacy safeguards and secure digital data storage. |
“Artificial intelligence is an incredible triaging assistant, but it is not a complete replacement for clinical oversight,” notes Dr. Ananya Sharma, a public health researcher specializing in health technology assessment. “An AI algorithm is only as good as the dataset it was trained on. As GrivaVision rolls out across diverse populations, independent field studies will be vital to verify that its sensitivity and specificity remain consistent across various clinical environments.”
Dr. Sharma also emphasizes that screening is only the first step in the continuum of care. “Finding a pre-cancerous lesion with an AI colposcope only saves a life if that patient is subsequently connected to effective, timely treatment. Screening infrastructure must be matched by equal investments in treatment pathways.”
What This Means for Everyday Health
For patients and health-conscious individuals, the arrival of portable, AI-assisted screening tools heralds a future where routine cancer screening is as simple as visiting a local community health clinic.
Healthcare bodies continue to emphasize that all women aged 21 to 65 should undergo regular cervical cancer screening, regardless of whether they exhibit symptoms. Early-stage cervical pre-cancers typically produce no noticeable symptoms, making routine checks vital.
Women are advised to consult their healthcare providers regarding the screening schedule best suited to their medical history, which may include HPV testing, Pap tests, or visual inspections via digital colposcopy.
Medical Disclaimer
This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References
-
Press Information Bureau (PIB), Government of India. “TDB-DST Supports M/s Griva Healthcare Pvt. Ltd., Vishakhapatnam for Commercialization of Indigenous AI-Powered Cervical Cancer Screening Technology.” Published August 10, 2026.
- https://www.pib.gov.in/PressReleasePage.aspx?PRID=2297106®=48&lang=1
Happy
0 %
Sad
0 %
Excited
0 %
Sleepy
0 %
Angry
0 %
Surprise
0 %
